

Polyunsaturated Fatty Acid Consumption May Play a Role in the Onset and Regression of Microalbuminuria in Well-Controlled Type 1 and Type 2 Diabetic People

A 7-year, prospective, population-based, observational multicenter study

THE DIABETES AND NUTRITION STUDY
GROUP OF THE SPANISH DIABETES
ASSOCIATION (GSEDNu)*

The risk of developing microalbuminuria at some point in the life of a diabetic patient has been estimated to be >60% (1,2). The main risk factors associated with the presence of microalbuminuria have already been identified (3–9). Recently, 32–58% regression of microalbuminuria in type 1 diabetic patients has been reported (10–13). Modifiable factors associated with regression, such as low blood pressure, low cholesterol and triglyceride levels, and HbA_{1c} <8%, suggest that diet can play a relevant role in reducing the risk of microalbuminuria (14–18).

The Diabetes and Nutrition Clinical Trial (DNCT) is a prospective, population-based, observational multicenter study designed to evaluate the nutritional pattern (based on 7-day food diaries) of diabetic patients in Spain and its relation with the development of diabetes complications. In this study, we report changes in nephropathy status and their connection with nutritional patterns that occurred during the 7-year follow-up in a sample of Spanish people with diabetes.

RESEARCH DESIGN AND METHODS

A total of 192 diabetic patients (93 type 1 diabetic and 99 type 2 diabetic patients) attended the four centers between 1993 and 2000 and completed the study. Selection criteria and a wide description of the experimental design have been previously reported (19,20). Diabetic nephropathy was defined by the albumin-to-creatinine ratio in the three first-morning urine samples.

Nephropathy progression was considered when diabetic patients were normoalbuminuric in 1993 and were micro- or macroalbuminuric in 2000 or if they had microalbuminuria in 1993 and macroalbuminuria in 2000. Patients were considered to have nephropathy regression if they presented with microalbuminuria in 1993 and normoalbuminuria in 2000 or if they presented with macroalbuminuria in 1993 and micro- or normoalbuminuria in 2000.

RESULTS — At baseline, 37 (19.3%) diabetic patients had diabetic nephropathy, 23 (12.0%) microalbuminuria, and

14 (7.3%) macroalbuminuria. After a median follow-up period of 6.5 years, 3 type 1 diabetic patients (nephropathy progression rate 3.9%, 0.6%/year) and 12 type 2 diabetic patients (nephropathy progression rate 15.2%, 2.3%/year) progressed to microalbuminuria and 2 type 1 diabetic patients (nephropathy progression rate 2.6%, 0.4%/year) progressed to macroalbuminuria. Two type 2 diabetic patients (nephropathy progression rate 16.7%, 2.6%/year) progressed from microalbuminuria to macroalbuminuria. Seven type 1 diabetic patients (nephropathy regression rate 63.6%, 9.8%/year) and two type 2 diabetic patients (nephropathy regression rate 16.7%, 2.6%/year) regressed from microalbuminuria to normoalbuminuria, whereas one type 1 diabetic patient (nephropathy regression rate 16.7%, 2.6%/year) and four type 2 diabetic patients (nephropathy regression rate 50%, 7.7%/year) passed from macroalbuminuria to microalbuminuria. One type 2 diabetic patient (nephropathy regression rate 12.5%, 1.9%/year) regressed from macroalbuminuria to normoalbuminuria. Table 1 shows the nutrient intake, clinical characteristics, and laboratory data of the study subjects by nephropathy status. The nutritional pattern of patients with nephropathy regression was characterized by greater polyunsaturated fatty acid (PUFA) and smaller saturated fatty acid (SFA) intakes than those of patients with nephropathy ($P < 0.05$), whereas the PUFA-to-SFA and monounsaturated fatty acid (MUFA)-to-SFA ratios were significantly greater ($P < 0.001$). The opposite pattern is associated with progression of nephropathy.

CONCLUSIONS — Different factors that can confuse the interpretation of

From the Department of Endocrinology and Nutrition, San Carlos University Hospital, Madrid, Spain.

Address correspondence and reprint requests to Alfonso L. Calle-Pascual, MD, PhD, Department of Endocrinology and Nutrition, 1SS, San Carlos University Hospital, c/Prof. Martín Lagos s/n, E-28040 Madrid, Spain. E-mail: acalle.hcsc@salud.madrid.org.

Received for publication 10 March 2004 and accepted in revised form 17 March 2004.

*A list of the members of the GSEDNu Study Group can be found in the APPENDIX.

Abbreviations: DNCT, Diabetes and Nutrition Clinical Trial; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2004 by the American Diabetes Association.

Table 1—Clinical characteristics, nutrient intake, and laboratory data for the diabetic subjects

	Normoalbuminuria	Change	Nephropathy	Change	Progression	Change	Regression	Change
n (men/women)	121 (47/74)	—	37 (18/19)	—	19 (11/8)	—	15 (7/8)	—
Age (years)	50 (28–64)	—	60 (41–73) ^a	—	67 (55–73) ^b	—	56.5 (37.7–73) ^c	—
Duration of disease (years)	19.8 (10.8–28.6)	—	20.3 (11.6–29.1)	—	19.3 (10.1–26.5)	—	17.8 (9.2–21.5)	—
Diabetic patients (type 1/type 2)	63/58	—	17/20	—	5/14	—	8/7	—
BMI (kg/m ²)	25.6 (22.6–28.9)	13.8	26.9 (23.8–32.5) ^a	4.6	29.0 (25.3–31.0) ^b	4.7	27.2 (24.0–30.1)	–7.7
Body weight (kg)	69.0 (60.7–75)	10.3	69.4 (62.9–85.4)	4.5	73.8 (66.8–81.6)	4.6	69.1 (66.0–85.3)	–7.5
Waist circumference (cm)	86.2 (74–97.7)	–5.6	98 (80.5–107.0) ^a	4.1	100.5 (88.5–108) ^b	5.7	89 (80–98.2) ^c	–6.1
HbA _{1c} (%)	7.1 (6.0–8.5)	–6.5	7.1 (5.6–9.3)	–6.7	7.0 (5.6–8.3)	–17.5	6.5 (6.0–8.0) ^c	–18.7
Systolic blood pressure (mmHg)	130 (112.5–145)	–3.1	140 (130–162.5) ^a	4.2	140 (130–156.2) ^b	3.7	130 (120–148.7) ^c	–2.1
Diastolic blood pressure (mmHg)	77 (70–80)	–3.5	80 (72.5–88.5) ^a	4.4	80 (78.7–87.7) ^b	1.1	75 (70–80) ^c	–1.1
Cholesterol (mmol/l)	5.17 (4.50–5.78)	–1.2	5.62 (4.66–6.05) ^a	–11.9	5.61 (4.57–6.12) ^b	1.3	4.92 (4.02–5.56) ^c	–17.3
HDL cholesterol (mmol/l)	1.63 (1.40–1.83)	23.0	1.43 (1.23–1.82) ^a	27.0	1.63 (1.42–1.78)	29.3	1.40 (1.14–1.65)	–23.8
LDL cholesterol (mmol/l)	3.03 (2.54–3.54)	–6.6	2.98 (2.44–3.71)	–9.2	3.14 (2.17–3.64) ^b	9.1	2.59 (1.93–3.62) ^c	0.5
Triglycerides (mmol/l)	0.84 (0.62–1.18)	3.4	1.25 (0.78–1.68) ^a	3.5	0.96 (0.78–1.18) ^b	–4.6	0.85 (0.57–1.18) ^c	–12.2
Apolipoprotein A1 (mg/dl)	149 (135–172.5)	NE	151.5 (137.2–170.7)	NE	158 (148–175)	NE	139 (118.2–171.7)	NE
Apolipoprotein B (mg/dl)	87 (70.4–105.5)	NE	99.4 (81.7–116.7) ^a	NE	96 (83.4–111) ^b	NE	81 (60.4–101.1) ^c	NE
Lipoprotein (a) (mg/dl)	12.3 (9.6–28.5)	NE	12.3 (9.6–38.4)	NE	16.7 (9.6–62.6) ^b	NE	15 (9.6–40.9)	NE
Energy (kcal/day)	1,803 (1,577–2,245)	5.3	1,806 (1,492–2,320)	–9.2	1,661 (1,322–1,998)	3.3	1,746 (1,473–2,198)	6.8
Carbohydrate								
Percentage	37.3 (34.0–42.7)	3.9	41.0 (36.7–43.0) ^a	0.8	36.8 (33.4–41.3)	–3.2	37.8 (34.0–41.0)	–5.5
Grams	177 (142–214)	9.0	185 (132–223)	11.7	159 (132–184)	–0.2	161 (120–232)	–4.6
Protein								
Percentage	19.2 (16.9–21.0)	–5.1	19.8 (15.3–23.3)	1.1	20.1 (17.8–24.0)	1.1	21.3 (18.0–23.4)	4.5
Grams	85 (75–103)	–1.8	87 (72–103)	9.3	84 (72–100)	0.6	91 (75–105)	2.6
g/kg body wt	1.23 (1.08–1.49)	–0.4	1.25 (1.03–1.48)	4.3	1.13 (0.97–1.35)	0.3	1.31 (1.08–1.51)	3.2
Total fat								
Percentage	40.5 (36.7–45.1)	8.4	39.5 (34.9–42.0)	1.2	39.4 (36.5–42.6)	11.8	42.2 (37.0–43.5)	18.7
Grams	83 (70–104)	1.8	82 (63–105)	6.2	71 (56–92) ^b	7.7	78 (68–88)	11.1
SFAs (%)	28.9 (22.8–37.3)	–7.7	37.8 (31.7–50.6) ^a	0.5	36.6 (29.5–45.0) ^b	2.5	29.4 (24.3–41.0) ^c	–24.1
MUFAs (%)	54.2 (46.9–68.6)	8.7	51.2 (39.2–63.4) ^a	0.7	52.1 (38.0–67.6)	–21.1	53.8 (46.1–65.4)	49.3
PUFAs (%)	16.8 (13.2–20.4)	12.6	10.9 (8.5–15.8) ^a	–3.7	11.2 (8.4–14.0) ^b	3.9	16.7 (15.3–19.2) ^c	26.8
Cholesterol (mg)	336 (282–431)	–1.2	353 (284–441)	11.3	355 (244–420)	1.2	389 (315–454)	–5.9
PUFA-to-SFA ratio	0.58 (0.35–0.73)	28.7	0.28 (0.21–0.34) ^a	–8.3	0.30 (0.25–0.38) ^b	8.5	0.56 (0.40–0.68) ^c	37.1
MUFA-to-SFA ratio	1.87 (1.55–2.27)	18.5	1.31 (1.12–1.61) ^a	2.3	1.41 (1.15–1.62) ^b	–31.9	1.82 (1.54–2.15) ^c	58.9
Fiber (g)	17 (13–20)	20.0	19 (15–25)	–10.5	18 (13–22)	–5.0	13 (10–20)	–4.2
Alcohol (g)	1.3 (0–7.7)	–0.0	0.5 (0–5.2)	–0.0	0 (0–8.5)	–0.0	0 (0–0.2)	0.1

Data are median (quartile 1 – quartile 3). Change was calculated as (value in year 2000 – value in year 1993) × 100/value in year 1993. ^a*P* < 0.05 and ^b*P* < 0.001, nephropathy versus normoalbuminuria; ^c*P* < 0.05 and ^d*P* < 0.001, progression versus normoalbuminuria; ^e*P* < 0.05 and ^f*P* < 0.001, regression versus nephropathy (Mann-Whitney and Kruskal-Wallis tests). NE, not evaluated in 1993.

these data have been analyzed in this study. Protein consumption could affect nephropathy progression (14–16,21,22). Even though the median of protein consumption in this study is closer to the recommended level (<20%), it is still >0.8 g/kg body wt, which is recommended when microalbuminuria is present. This could explain why no association was found between protein consumption and nephropathy. When regression patients were compared with nonregression patients, both groups were treated with ACE inhibitors and/or angiotensin receptor blockers as expected, and no difference was obtained. We have also evaluated the existence of polymorphisms of different alleles potentially associated with nephropathy. Although the presence of risk polymorphism alleles in this population is greater than that in the nondiabetic population (23), we did not observe any associations with nephropathy progression or regression, indicating that this nonmodifiable factor is not determined in the evolution of nephropathy, as previously described (24).

According to the data obtained in our study, normoalbuminuria and nephropathy regression in well-controlled diabetic patients with long-term diabetes duration are associated with greater PUFA consumption and lesser SFA consumption and specifically with higher PUFA-to-SFA and MUFA-to-SFA ratios, whereas the opposite pattern is associated with the progression of nephropathy.

Various mechanisms that relate to the type of fat intake and microalbuminuria development may explain these findings. The consumption of SFAs induces insulin resistance and a hypercoagulable state and in turn worsens diabetes metabolic control (25,26). PUFAs inhibit platelet aggregation and inflammation, reduce some proatherogenic factors, and reduce triglyceride, chylomicron, and lipoprotein(a) levels, and an increase in MUFA or PUFA consumption favorably modifies lipid profiles and reduces their oxidative capacity (25–29). A strong association between MUFA-to-SFA and PUFA-to-SFA ratios and decreased cardiovascular mortality has recently been described (30). The present study data support this hypothesis. Therefore, both ratios are nutritional variables that allow us to more clearly differentiate the patients who are going to regress or progress.

The present study findings are poten-

tially important: first, because microalbuminuria is associated with an increment in cardiovascular mortality in both type 1 and type 2 diabetic patients and, second, because its prevalence is high. Micro- and macroalbuminuria do not have to inevitably progress to end-stage kidney disease, whereas the regression from both conditions is quite frequent. Strict control of glycemia and blood pressure should be a priority. Treatment with ACE inhibitors and/or angiotensin receptor blockers and cessation of smoking remain the therapeutic objectives for modifiable risk factors. When these objectives are attained, other therapeutic measures, such as encouraging PUFA and MUFA consumption over that of SFA, can help prevent micro- and macroalbuminuria. Keeping in mind that nutritional patterns are the base of integral diabetes care, more efforts should be directed to increase PUFA and MUFA intake and to reduce SFA consumption, particularly in people with diabetes and nephropathy.

APPENDIX

The Diabetes and Nutrition Study Group (GSEDNU)

P. Manzano, MD, Service of Endocrinology and Nutrition, Clínica Puerta de Hierro, Madrid, Spain; A. Picó, MD, Service of Endocrinology and Nutrition, Alicante General Hospital, Alicante, Spain; F. Casimiro-Soriguer (coordinator), MD, S. Gonzalez, MD, and F. Tinahones, MD, Service of Endocrinology and Nutrition, CSCH, Málaga, Spain; E. León, RN, and P. Matia, MD, CEP Hermanos Sangro, Madrid, Spain; A.L. Calle-Pascual (coordinator), MD, PhD, M.P. de Miguel, MD, M.A. Rubio, MD, E. Bordiu, PhD, J.R. Calle, MD, A.L. Charro, MD, PhD, Department of Endocrinology and Nutrition, and J. Bagazgoitia, PhD, Diabetes Laboratory, San Carlos University Hospital, Madrid, Spain; P.J. Martín-Alvarez, PhD, CSIC, Madrid, Spain; and A. Coloma, MD, PhD, A. Ocaña, MD, PhD, Molecular Genetic Laboratory, King Juan Carlos University (URJC), Mostoles, Madrid, Spain.

This work was written on behalf of the Diabetes and Nutrition Study Group of the Spanish Diabetes Association by C. Cárdenas, MD, E. Bordiu, PhD, J. Bagazgoitia, PhD, and A.L. Calle-Pascual, MD, PhD, Department of Endocrinology and Nutrition, San Carlos University Hospital,

Madrid, Spain. All of the investigators from all of the centers also provided comments on relevant aspects of the drafts.

References

1. Warram JH, Gearin G, Laffel L, Krolewski AS: Effect of duration of type 1 diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. *J Am Soc Nephrol* 7:930–937, 1996
2. Niskanen LK, Penttilä I, Parviainen M, Uusitupa MIJ: Evolution, risk factors, and prognostic implications of albuminuria in NIDDM. *Diabetes Care* 19:486–493, 1996
3. Rossing P, Hougaard P, Parving HH: Risk factors for development of incipient and over diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. *Diabetes Care* 25:859–864, 2002
4. Microalbuminuria Collaborative Study Group: Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven-year prospective study. *Diabet Med* 16:918–925, 1999
5. Mattock MB, Cronin N, Cavallo-Perin P, Idzior-Walus B, Penno G, Bandinelli S, Standl E, Kofinis A, Fuller JH, EURODIAB IDDM Complications Study: Plasma lipids and urinary albumin excretion rate in type 1 diabetes mellitus: the EURODIAB IDDM Complications Study. *Diabet Med* 18:59–67, 2001
6. Gambaro G, Bax G, Fusaro M, Normanno M, Manani SM, Zanella, Dangelo A, Fedele D, Favaro S: Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. *Diabetes Nutr Metab* 14:337–342, 2001
7. Torffvit O, Agardh CD: The impact of metabolic and blood pressure control on incidence and progression of nephropathy: a 10-year study in 385 type 2 diabetic patients. *J Diabetes Complications* 15:307–313, 2001
8. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH: Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. *Kidney Int* 60:219–227, 2001
9. Bruno G, Cavallo-Perin P, Barger G, Borra M, Calvi V, D'Errico D, Deambrogio P, Pagano G: Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of NIDDM subjects. *Diabetes Care* 19:43–47, 1996
10. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS: Regression of microalbuminuria in type 1 diabetes. *N Engl J Med* 348:2285–2293, 2003
11. Bojestig M, Arnqvist HJ, Karlberg BE,

- Ludvigsson J: Glycemic control and prognosis in type 1 diabetic patients with microalbuminuria. *Diabetes Care* 19:313–317, 1996
12. Kullberg CE, Arnqvist HJ: Glycemic control in patients with type 1 diabetes and normoalbuminuria after long diabetes duration. *J Diabetes Complications* 11: 151–157, 1997
 13. Ruberg S, Dahlquist G: Determinants of progression of microalbuminuria in adolescents with IDDM. *Diabetes Care* 19: 369–371, 1996
 14. Toeller M, Buyken A, Heitkamp G, Bräm-swig S, Mann J, Milne R, Gries FA, Keen H, EURODIAB IDDM Complications Study Group: Protein intake and urinary albumin excretion rates in the EURO-DIAB IDDM Complications Study. *Diabetologia* 40:1219–1226, 1997
 15. Pijls LT, de Vries H, Donker AJ, van Eijk JT: The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial. *Nephrol Dial Transplant* 14:1445–1453, 1999
 16. Riley MD, Dwyer T: Microalbuminuria is positively associated with usual dietary saturated fat intake and negatively associated with usual dietary protein intake in people with insulin-dependent diabetes mellitus. *Am J Clin Nutr* 67:50–57, 1998
 17. Franz MJ, Wheeler ML: Nutrition therapy for diabetic nephropathy. *Curr Diab Rep* 3:412–417, 2003
 18. American Diabetes Association: Diabetic nephropathy (Position Statement). *Diabetes Care* 26 (Suppl. 1):S94–S98, 2003
 19. Diabetes and Nutrition Study Group of the Spanish Diabetes Association (GSEDNu): Diabetes Nutrition and Complications Trial (DNCT): food intake and targets of diabetes treatment in a sample of Spanish people with diabetes. *Diabetes Care* 20: 1078–1080, 1997
 20. Diabetes and Nutrition Study Group of the Spanish Diabetes Association (GSEDNu): Diabetes Nutrition and Complications Trial: trends in nutritional pattern between 1993 and 2000 and targets of diabetes treatment in a sample of Spanish people with diabetes. *Diabetes Care* 27: 984–987, 2004
 21. Bouhanick B, Hadjadj S, Marre M: Microalbuminuria, glomerular filtration rate and dietary fat and protein intakes in type 1 diabetes (Letter). *Am J Clin Nutr* 69: 153, 1999
 22. Möllsten AV, Dahlquist GG, Stattin EL, Rudberg S: Higher intakes of fish protein are related to a lower risk of microalbuminuria in young Swedish type 1 diabetic patients. *Diabetes Care* 24:805–810, 2001
 23. Ocaña A, Coloma A, Grupo de la Sociedad Española de Diabetes para el estudio de la Nutrición: Factores genéticos de riesgo micro- y macrovascular en la diabetes mellitus [in Spanish]. *Av Diabetol* 19:115–120, 2003
 24. Krolewski AS: Genetics of diabetic nephropathy: evidence for major and minor gene effects. *Kidney Int* 55:1582–1596, 1999
 25. Summers LK, Fielding BA, Bradshaw HA, Ilic V, Beysen C, Clark ML, Moore NR, Frayn KN: Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution and improves insulin sensitivity. *Diabetologia* 45:369–377, 2002
 26. Harding AH, Sargeant LA, Welch A, Oakes S, Luben RN, Bingham S, Day NE, Khaw KT, Wareham NJ: Fat consumption and HbA_{1c} levels. *Diabetes Care* 24:1911–1916, 2001
 27. Hu FB: The Mediterranean diet and mortality: olive oil and beyond. *N Engl J Med* 348:2595–2596, 2003
 28. Ramirez-Tortosa MC, Lopez-Pedrosa JM, Suarez A, Ros E, Mataix J, Gil A: Olive oil and fish oil enriched diets modify plasma lipids and the susceptibility of low-density lipoproteins to oxidative modification in free-living male patients with peripheral vascular disease: the Spanish Nutrition Study. *Br J Nutr* 82:31–39, 1999
 29. Ramirez-Tortosa MC, Lopez-Pedrosa JM, Suarez A, Ros E, Mataix J, Gil A: Effect of extra-virgin olive oil and fish oil supplementation on plasma lipids and susceptibility of low-density lipoproteins to oxidative alteration in free-living Spanish male patients with peripheral vascular disease. *Clin Nutr* 18:167–174, 1999
 30. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D: Adherence to a Mediterranean diet and survival in a Greek population. *N Engl J Med* 348:2599–2608, 2003